Approved Products | Virtual Congress | Novartis HCP

This site is for health care professionals only.

Featured Congresses

2022 ASCO Annual Meeting

EHA 2022 Virtual Congress

WCLC 2022

ESMO Congress 2022

EANM 2022 Congress

SABCS 2022

2022 ASH Annual Meeting

.atomic-select.jsAtomicSelect { display: none; }

.atomic-navigation-links__li._lvl1:hover .atomic-navigation-links__ul._lvl2 { display: block; } .atomic-navigation-links__li._lvl1:hover .atomic-navigation-links__plus-expand-icon { display: none; } .atomic-navigation-links__li._lvl1:hover .atomic-navigation-links__minus-expand-icon { display: block; }

Our 4 Bold Approaches to Cancer Treatment

Solid Tumors

Solid Tumors

KISQALI® (ribociclib)

LOCAMETZ® (kit for the preparation of gallium Ga 68 gozetotide injection)

LUTATHERA® (lutetium Lu 177 dotatate)

PIQRAY® (alpelisib)

PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)

TABRECTA® (capmatinib)

TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)

Vijoice® (alpelisib)

Malignant Hematology

Malignant Hematology

KYMRIAH® (tisagenlecleucel) CAR-T Cell Therapy

Prescribing Information, including Boxed WARNING

RYDAPT® (midostaurin)

SCEMBLIX® (asciminib)

TASIGNA® (nilotinib)

Prescribing Information, including Boxed WARNING

Non-malignant Hematology

Non-malignant Hematology

ADAKVEO® (crizanlizumab-tmca)

PROMACTA® (eltrombopag)

Prescribing Information, including Boxed WARNING

Patient Assistance Now Oncology (PANO)

The single source for patient support throughout the Novartis Oncology experience.

.lazy { display: none; }

Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2022 Novartis AG. All rights reserved.

US: 4/22 158684

Non-US: 9/22 124229-3